ResMed Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael J. Farrell
- Full Time Employees
- 11,370
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 9001 Spectrum Center Boulevard San Diego CA United States of America 92123
- IPO Date
- Jun 2, 1995
- CIK
- 0000943819
- Website
- resmed.com
- Similar Companies
- Business
- ResMed Inc. (NYSE: RMD; ASX: RMD) develops, manufactures, distributes and markets cloud-connected medical devices, digital health technologies and software platforms that diagnose, treat and manage sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), respiratory insufficiency and other chronic diseases. The company offers continuous positive airway pressure (CPAP) and automatic positive airway pressure (APAP) devices including the AirSense and Air11 series; masks and accessories such as the AirFit, AirTouch N30i and F30i fabric-based platforms; ventilators like the Lumis series for non-invasive support; humidifiers including HumidCare; portable options such as AirMini; and software solutions encompassing myAir for patient self-monitoring, AirView for remote clinician oversight, and SaaS platforms for out-of-hospital care providers including residential care management tools. It operates through two primary segments: Sleep and Respiratory Care, addressing obstructive sleep apnea, central sleep apnea, overlap syndrome, obesity hypoventilation and neuromuscular diseases; and Software as a Service (SaaS), supporting healthcare professionals with data-driven platforms. ResMed serves patients, clinicians, sleep labs, homecare providers and health systems in over 140 countries, with key growth markets in the United States, Canada, Latin America, Europe, China, South Korea, India, Brazil and Eastern Europe. Founded in 1989 by Dr. Peter Farrell in Sydney, Australia, to commercialize CPAP technology, the company is headquartered in San Diego, California, and employs approximately 10,600 people. Recent developments include the May 2025 acquisition of VirtuOx, a leading independent diagnostic testing facility for at-home sleep, respiratory and cardiac testing, which operates as a wholly owned subsidiary to streamline diagnostics, enhance virtual care coordination and expand into adjacent areas like insomnia; launches of new AirTouch F30i mask variants including the comfort edition in Australia and clear edition in the U.S.; strategic U.S. manufacturing and distribution expansion in Indianapolis; and a board leadership change with director Richard Sulpizio departing following the 2025 annual stockholders' meeting.
Company News
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
ResMed: A Significant Upside Despite The Perceived Risk
The IRS Lets You Send Your RMD Straight to Charity and Skip the Tax Entirely. These 3 ETFs Replace the Income You Gave Away
ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Canada Pension Plan Investment Board Buys New Position in ResMed Inc. $RMD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
The IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching a Share
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor